28 September 2021 - Saphnelo is a first in class type I interferon receptor antibody shown to reduce overall disease activity in patients with systemic lupus erythematosus.
AstraZeneca’s Saphnelo (anifrolumab) has been approved in Japan for the treatment of adult patients with systemic lupus erythematosus, a serious auto-immune disease, who show insufficient response to currently available treatment.